SBIR Phase I: High-speed Low-cost Spectral Domain Optical Coherence Tomography System for Intravascular Imaging Applications

SBIR 第一阶段：用于血管内成像应用的高速低成本谱域光学相干断层扫描系统

• 批准号: 1112990
• 负责人: William Brown
• 金额: $ 14.98万
• 依托单位: Wasatch Photonics, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1112990&HistoricalAwards=false
• 关键词: SBIR; Phase; speed; Low; cost

This Small Business Innovation Research (SBIR) Phase I project seeks to demonstrate that 840 nm spectral domain optical coherence tomography (OCT) can provide images equal to or better than those currently available from swept source OCT, with the added advantages of higher imaging speeds and lower cost. Intravascular OCT is poised for commercial growth, but is still limited by technical complexity, availability, and cost. This Phase I SBIR proposes a complete prototype system based on a very high resolution (0.02 nm/pixel) spectrometer, capable of imaging 5 mm deep with a resolution of 10 microns. A novel fiber probe will be designed and prototyped. Proof of principle data will be collected from tissue phantoms and waste animal tissue. Pending successful completion of a Phase I, a Phase II project would complete system engineering, decrease system cost, and target first in-human imaging.The broader impact/commercial potential of this project is an increase in performance and availability of intravascular OCT (IV-OCT). Intravascular OCT provides detailed imaging information for plaque assessment, stent implantation, and stent monitoring over time. Identification and treatment of unstable plaques and other intravascular conditions can reduce the morbidity and mortality rate from coronary artery disease (CAD). CAD is the primary cause of heart attacks and strokes, which killed over 631,000 and 137,000 people, respectively, in the U.S in 2006. The market size for intravascular OCT is estimated at more than $1B annually, but there is currently only one commercially available IV-OCT system. By increasing system speed and reducing cost, this project will accelerate clinical use of IV-OCT.

该小型企业创新研究（SBIR）第一阶段项目旨在证明840 nm谱域光学相干断层扫描（OCT）可以提供与目前扫频光源OCT相同或更好的图像，并具有更高的成像速度和更低的成本。 血管内OCT有望实现商业化增长，但仍受到技术复杂性、可用性和成本的限制。 这第一阶段SBIR提出了一个完整的原型系统的基础上，非常高的分辨率（0.02纳米/像素）光谱仪，能够成像5毫米深的分辨率为10微米。 设计了一种新型的光纤探头，并制作了样机。 将从组织模型和废弃动物组织中收集原理数据证明。 在第一阶段成功完成之前，第二阶段项目将完成系统工程，降低系统成本，并首次瞄准人体成像。该项目更广泛的影响/商业潜力是提高血管内OCT（IV-OCT）的性能和可用性。 血管内OCT提供了斑块评估、支架植入和支架随时间监测的详细成像信息。 识别和治疗不稳定斑块和其他血管内疾病可以降低冠状动脉疾病（CAD）的发病率和死亡率。 CAD是心脏病发作和中风的主要原因，2006年在美国分别造成631，000和137，000人死亡。 血管内OCT的市场规模估计每年超过10亿美元，但目前只有一种市售IV-OCT系统。 通过提高系统速度和降低成本，该项目将加速IV-OCT的临床应用。